E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors—design and rationale

Authors

Institutions

Publication Details

Journal
Future Oncology
Published
2025-05-27
DOI
https://doi.org/10.1080/14796694.2025.2497719
Citations
1
Primary Topic
Ovarian cancer diagnosis and treatment
Type
article
Field-Weighted Citation Impact
1.70

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors—design and rationale

Sandeep Gurram, Ruchi P. Patel, Andre R. Kydd, Elias Chandran et al.
1 citations
Future Oncology
Ovarian cancer diagnosis and treatment
1.70
article

E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors—design and rationale

Sandeep Gurram, Ruchi P. Patel, Andre R. Kydd, Elias Chandran, Nicholas I. Simon, Andrea B. Apolo, Lisa M. Cordes, Seth M. Steinberg, Scot A. Niglio, Ian Stukes, Saad Atiq, Tzu-Fang Wang, Salah Boudjadi, Bernadette Redd, Dilara Akbulut, Daniel M. Girardi, Rouf Banday, Elizabeth Smith, Lisa Ley
article en
1 citations

Abstract

No abstract available for this paper.
Future OncologyVol. 21(13)
National Institutes of Health (US), NYU Langone Health (US), Office of the Director (US), Hinge Health (US), National Cancer Institute (US), Center for Cancer Research (US)
Merck, Astellas Pharma
Zero hunger
Openalex Percentile: Top 17%
Ovarian cancer diagnosis and treatment
1.70
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors—design and rationale — Sandeep Gurram, Ruchi P. Patel, et al. · Future Oncology (2025) | TGRS Research Map | TGRS